Ceshi Chen
Overview
Explore the profile of Ceshi Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
163
Citations
4082
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kong Y, Lan T, Wang L, Gong C, Lv W, Zhang H, et al.
Oncogene
. 2025 Feb;
44(8):557.
PMID: 39900726
No abstract available.
2.
Tang Y, Liu R, Zhu J, He Q, Pan C, Zhou Z, et al.
Adv Sci (Weinh)
. 2025 Jan;
:e2412096.
PMID: 39888288
Basal-like breast cancer (BLBC), overlapping with the subgroup of estrogen receptor (ER), progesterone receptor (PR), and HER2 triple-negative breast cancer, has the worst prognosis and limited therapeutics. The XPO1 gene...
3.
Huang Y, Lu H, Liu Y, Wang J, Xia Q, Shi X, et al.
EMBO J
. 2025 Jan;
44(5):1414-1441.
PMID: 39875724
mTOR plays a pivotal role in cancer growth control upon amino acid response. Recently, CDK inhibitor P27KIP1 has been reported as a noncanonical inhibitor of mTOR signaling in MEFs, via...
4.
Xia J, Zhang L, Zhu W, Tu J, Peng X, Deng Q, et al.
Sci Bull (Beijing)
. 2025 Jan;
PMID: 39800628
Neurotransmitters are increasingly recognized to play important roles in limiting anti-tumor immunity. N-acetyl-aspartyl-glutamate (NAAG) has been extensively studied in neurological disorders; however, its potential role in restricting anti-tumor immunity has...
5.
Guo Y, Li Y, Zhou Z, Hou L, Liu W, Ren W, et al.
J Exp Clin Cancer Res
. 2024 Nov;
43(1):314.
PMID: 39614393
Background: Triple-negative breast cancer (TNBC) is currently the most aggressive subtype of breast cancer, characterized by high heterogeneity and strong invasiveness, and currently lacks effective therapies. PRMT5, a type II...
6.
Ren W, Liang H, Sun J, Cheng Z, Liu W, Wu Y, et al.
Cell Death Dis
. 2024 Nov;
15(11):821.
PMID: 39532855
Angiogenesis is well known to play a critical role in breast cancer. We previously reported that TNFAIP2 activates Rac1 to promote triple-negative breast cancer (TNBC) cell proliferation, migration, and chemoresistance....
7.
Huang M, Liu W, Cheng Z, Li F, Kong Y, Yang C, et al.
Cell Death Discov
. 2024 Nov;
10(1):462.
PMID: 39487119
Triple negative breast cancer is the most malignant subtype of breast cancer and current treatment options are limited. Radiotherapy is one of the primary therapeutic options for patients with TNBC....
8.
Wang L, Hu Z, Bai H, Chang L, Chen C, Li W
Am J Med Sci
. 2024 Sep;
PMID: 39313115
Background: Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer (BC). Some potential molecular targets have been identified, and miR-105-5p was found to be abnormally expressed in TNBC...
9.
Kong Y, Lan T, Wang L, Gong C, Lv W, Zhang H, et al.
Oncogene
. 2024 Aug;
43(39):2914-2926.
PMID: 39164524
Interest in the use of proteolysis-targeting chimeras (PROTACs) in cancer therapy has increased in recent years. Targeting bromodomain and extra terminal domain (BET) proteins, especially bromodomain-containing protein 4 (BRD4), has...
10.
Liu W, Sun X, Li F, Jiang Q, An J, Wu Y, et al.
J Adv Res
. 2024 Aug;
PMID: 39142440
Introduction: Homologous recombination repair during meiosis is essential for the exchange of genetic information between sister chromosomes, underpinning spermatogenesis and, consequently, fertility. The disruption of this process can lead to...